Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Persistent corneal defect caused by Listeria monocytogenes

R A Eiferman1, K T Flaherty, A K Rivard

  • 1Department of Ophthalmology and Visual Sciences, University of Louisville, KY.

American Journal of Ophthalmology
|January 15, 1990
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

NPJ precision oncology·2022
Same author

Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Image-guided biopsy in the age of personalised medicine: strategies for success and safety.

Clinical radiology·2020
Same author

Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect.

The British journal of dermatology·2020
Same author

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

Annals of oncology : official journal of the European Society for Medical Oncology·2019